OA12165A - Dérivés aminés de dihydro-1,3,5-triazine et leurs applications en thérapeutique. - Google Patents

Dérivés aminés de dihydro-1,3,5-triazine et leurs applications en thérapeutique. Download PDF

Info

Publication number: OA12165A
Authority: OA; OAPI
Prior art keywords: aryl; alkoxy; alkyl; substituted; halogen
Prior art date: 2000-01-26

Application number

OA1200200225A

Other languages

English (en)

French (fr)

Inventor

Gerard Moinet

Daniel Cravo

Liliane Doare

Micheline Kergoat

Didier Mesangeau

Original Assignee

Lipha

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-26

Filing date

2001-01-25

Publication date

2006-05-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8846333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12165(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-25 Application filed by Lipha filed Critical Lipha

2006-05-08 Publication of OA12165A publication Critical patent/OA12165A/fr

Links

239000003814 drug Substances 0.000 title claims 5
150000001412 amines Chemical class 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 44
230000007170 pathology Effects 0.000 claims abstract description 5
208000031773 Insulin resistance syndrome Diseases 0.000 claims abstract description 4
-1 amino, hydroxy thio Chemical group 0.000 claims description 115
125000003545 alkoxy group Chemical group 0.000 claims description 69
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 62
125000000217 alkyl group Chemical group 0.000 claims description 55
125000003118 aryl group Chemical group 0.000 claims description 48
229910052736 halogen Inorganic materials 0.000 claims description 40
150000002367 halogens Chemical group 0.000 claims description 39
125000003282 alkyl amino group Chemical group 0.000 claims description 35
125000004093 cyano group Chemical group *C#N 0.000 claims description 33
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 33
125000006715 (C1-C5) alkylthio group Chemical group 0.000 claims description 28
125000005915 C6-C14 aryl group Chemical group 0.000 claims description 25
229910052739 hydrogen Inorganic materials 0.000 claims description 15
229910052760 oxygen Inorganic materials 0.000 claims description 15
229910052717 sulfur Inorganic materials 0.000 claims description 14
125000005842 heteroatom Chemical group 0.000 claims description 13
229910052799 carbon Inorganic materials 0.000 claims description 11
229910052757 nitrogen Inorganic materials 0.000 claims description 10
230000015572 biosynthetic process Effects 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
206010012601 diabetes mellitus Diseases 0.000 claims description 7
125000004414 alkyl thio group Chemical group 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 6
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
125000003367 polycyclic group Chemical group 0.000 claims description 5
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
206010059245 Angiopathy Diseases 0.000 claims description 3
125000001072 heteroaryl group Chemical group 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
150000007522 mineralic acids Chemical class 0.000 claims description 3
230000004770 neurodegeneration Effects 0.000 claims description 3
208000015122 neurodegenerative disease Diseases 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000002798 polar solvent Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 2
208000024827 Alzheimer disease Diseases 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
206010039966 Senile dementia Diseases 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
150000007524 organic acids Chemical class 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 4
125000004432 carbon atom Chemical group C* 0.000 claims 3
125000006649 (C2-C20) alkynyl group Chemical class 0.000 claims 1
125000005914 C6-C14 aryloxy group Chemical group 0.000 claims 1
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
125000002877 alkyl aryl group Chemical group 0.000 claims 1
125000004104 aryloxy group Chemical group 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
238000000034 method Methods 0.000 claims 1
101150035983 str1 gene Proteins 0.000 claims 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 53
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 8
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000700159 Rattus Species 0.000 description 4
150000001721 carbon Chemical group 0.000 description 4
IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
229910052727 yttrium Inorganic materials 0.000 description 3
229940123208 Biguanide Drugs 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
230000003178 anti-diabetic effect Effects 0.000 description 2
150000004283 biguanides Chemical class 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
XYDLIZKNTRKHRO-UHFFFAOYSA-N 2-n,2-n,6-n,6-n,4-pentamethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine;hydrochloride Chemical compound Cl.CC1N=C(N(C)C)NC(N(C)C)=N1 XYDLIZKNTRKHRO-UHFFFAOYSA-N 0.000 description 1
108010005094 Advanced Glycation End Products Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000008274 fructosamines Chemical class 0.000 description 1
230000036252 glycation Effects 0.000 description 1
229940015043 glyoxal Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
239000004137 magnesium phosphate Substances 0.000 description 1
229960002261 magnesium phosphate Drugs 0.000 description 1
229910000157 magnesium phosphate Inorganic materials 0.000 description 1
235000010994 magnesium phosphates Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229960002275 pentobarbital sodium Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
125000002345 steroid group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200200225A 2000-01-26 2001-01-25 Dérivés aminés de dihydro-1,3,5-triazine et leurs applications en thérapeutique. OA12165A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0000996A FR2804113B1 (fr)	2000-01-26	2000-01-26	Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

Publications (1)

Publication Number	Publication Date
OA12165A true OA12165A (fr)	2006-05-08

Family

ID=8846333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200225A OA12165A (fr)	2000-01-26	2001-01-25	Dérivés aminés de dihydro-1,3,5-triazine et leurs applications en thérapeutique.

Country Status (36)

Country	Link
US (4)	US7034021B2 (de)
EP (1)	EP1250328B2 (de)
JP (1)	JP4926357B2 (de)
KR (1)	KR100722438B1 (de)
CN (1)	CN1195743C (de)
AP (1)	AP2002002578A0 (de)
AR (1)	AR027293A1 (de)
AT (1)	ATE332294T1 (de)
AU (1)	AU782307B2 (de)
BG (1)	BG106933A (de)
BR (1)	BRPI0107815B8 (de)
CA (1)	CA2397636C (de)
CY (1)	CY1105344T1 (de)
CZ (1)	CZ303445B6 (de)
DE (1)	DE60121294T3 (de)
DK (1)	DK1250328T4 (de)
EA (1)	EA005378B1 (de)
EE (1)	EE05003B1 (de)
ES (1)	ES2267715T5 (de)
FR (1)	FR2804113B1 (de)
HR (1)	HRP20020625A2 (de)
HU (1)	HU230790B1 (de)
IL (1)	IL150530A0 (de)
IS (1)	IS6467A (de)
MA (1)	MA25650A1 (de)
MX (1)	MXPA02007232A (de)
NO (1)	NO20023532L (de)
OA (1)	OA12165A (de)
PL (1)	PL205345B1 (de)
PT (1)	PT1250328E (de)
SI (1)	SI1250328T2 (de)
SK (1)	SK287647B6 (de)
TN (1)	TNSN01012A1 (de)
WO (1)	WO2001055122A1 (de)
YU (1)	YU55602A (de)
ZA (1)	ZA200205314B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2804113B1 (fr) *	2000-01-26	2004-06-18	Lipha	Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
US7622469B2 (en)	2002-12-17	2009-11-24	Hamari Chemicals, Ltd.	2,4-diamino-1,3,5-triazine derivatives
FR2853650B1 (fr) *	2003-04-10	2006-07-07	Merck Sante Sas	Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
ATE489370T1 (de) *	2005-06-14	2010-12-15	Schering Corp	Herstellung und verwendung von verbindungen als aspartylproteasehemmer
FR2896160B1 (fr) *	2006-01-13	2008-04-25	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896158B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) *	2006-01-13	2008-04-04	Merck Sante Soc Par Actions Si	Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
DE102007054416A1 (de) *	2007-11-13	2009-05-14	Studiengesellschaft Kohle Mbh	Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de)	2008-02-02	2009-08-06	Merck Patent Gmbh	Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
ATE536347T1 (de)	2008-05-20	2011-12-15	Merck Sharp & Dohme	Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren
US20110124860A1 (en) *	2008-05-23	2011-05-26	Aubourg Stephanie	Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
WO2010024225A1 (ja) *	2008-08-25	2010-03-04	浜理薬品工業株式会社	新規ジヒドロトリアジン誘導体
ES2530223T3 (es)	2008-12-12	2015-02-27	Poxel S.A.S.	Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
JP5485292B2 (ja) *	2008-12-12	2014-05-07	ポクセル・エスアーエス	Ａｍｐｋ活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
WO2010103040A1 (en)	2009-03-10	2010-09-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
US8742102B2 (en)	2009-03-26	2014-06-03	Poxel	Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948028B1 (fr)	2009-07-17	2011-12-02	Merck Sante Sas	Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
FR2948027A1 (fr) *	2009-07-17	2011-01-21	Merck Sante Sas	Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr)	2009-07-17	2011-12-02	Merck Sante Sas	Derives amines de dihydro-1,3,5-triazine
WO2011154496A1 (en)	2010-06-09	2011-12-15	Poxel	Treatment of type 1 diabetes
TWI436768B (zh)	2010-06-09	2014-05-11	Poxel	第２型糖尿病之治療
EP2646422B1 (de)	2010-12-01	2015-07-08	Poxel	Trennung von triazinderivatenantiomeren durch weinsäure
RU2658819C2 (ru) *	2016-05-26	2018-06-25	федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет"	Применение гетероциклических гидразонов в качестве средств, обладающих антигликирующей активностью
FR3068601B1 (fr) *	2017-07-05	2021-02-19	Eric Joseph Marie Fulgence Janin	Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
EP3691650A1 (de)	2017-10-02	2020-08-12	Poxel	Verfahren zur behandlung von herzversagen mit bewahrter ejektionsfraktion
MY203360A (en) *	2018-06-06	2024-06-26	Metavant Sciences Gmbh	Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en)	2018-06-14	2019-12-19	Poxel	Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
WO2022152138A1 (zh) *	2021-01-15	2022-07-21	中国医药研究开发中心有限公司	稠和杂环类化合物及其制备方法和医药用途
CN118955413A (zh) *	2024-07-25	2024-11-15	宁夏恒康科技有限公司	一种盐酸伊美格列明的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3287366A (en) *	1963-12-24	1966-11-22	American Cyanamid Co	Novel 1, 2-dihydro-s-triazines
US3286366A (en) *	1964-10-26	1966-11-22	Seligman Monroe	Apparatus for freeze drying products in small containers
JPS4856692A (de) *	1971-11-19	1973-08-09
JPS4864088A (de) *	1971-12-13	1973-09-05
JPS5414986A (en) *	1977-07-01	1979-02-03	Taiho Pharmaceutical Co Ltd	Production of dihydrooss triazine derivative
US4246408A (en) *	1979-03-08	1981-01-20	Icn Pharmaceuticals	Imidazo[1,2-a]-s-triazine
GR74944B (de) *	1980-07-02	1984-07-12	Merck & Co Inc
US4277602A (en) *	1980-07-02	1981-07-07	Merck & Co., Inc.	3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4576945A (en) *	1982-10-26	1986-03-18	Sanders Mark E	Hexaalkylmelamine-amino-oxy compounds
JPS6141915A (ja)	1984-08-03	1986-02-28	Omron Tateisi Electronics Co	測距装置
DD257010A1 (de) *	1987-01-13	1988-06-01	Berlin Chemie Veb	Ergotrope mittel
DE3801113A1 (de) *	1987-07-23	1989-02-02	Bayer Ag	Substituierte triazine
IT1244870B (it) *	1990-09-11	1994-09-12	Ministero Dall Uni E Della Ric	Composti ammelinici
DE19641692A1 (de) *	1996-10-10	1998-04-23	Bayer Ag	Substituierte 2,4-Diamino-1,3,5-triazine
CN1290264A (zh) *	1997-12-12	2001-04-04	艾博特公司	三嗪类血管生成抑制剂
FR2804113B1 (fr) *	2000-01-26	2004-06-18	Lipha	Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

2000
- 2000-01-26 FR FR0000996A patent/FR2804113B1/fr not_active Expired - Lifetime
2001
- 2001-01-24 TN TNTNSN01012A patent/TNSN01012A1/fr unknown
- 2001-01-25 PT PT01907700T patent/PT1250328E/pt unknown
- 2001-01-25 OA OA1200200225A patent/OA12165A/fr unknown
- 2001-01-25 PL PL357191A patent/PL205345B1/pl unknown
- 2001-01-25 AT AT01907700T patent/ATE332294T1/de active
- 2001-01-25 MX MXPA02007232A patent/MXPA02007232A/es active IP Right Grant
- 2001-01-25 AU AU35603/01A patent/AU782307B2/en not_active Expired
- 2001-01-25 WO PCT/FR2001/000241 patent/WO2001055122A1/fr not_active Ceased
- 2001-01-25 CZ CZ20022462A patent/CZ303445B6/cs not_active IP Right Cessation
- 2001-01-25 AP APAP/P/2002/002578A patent/AP2002002578A0/en unknown
- 2001-01-25 HU HU0204087A patent/HU230790B1/hu unknown
- 2001-01-25 KR KR1020027009459A patent/KR100722438B1/ko not_active Expired - Lifetime
- 2001-01-25 SI SI200130600T patent/SI1250328T2/sl unknown
- 2001-01-25 SK SK976-2002A patent/SK287647B6/sk not_active IP Right Cessation
- 2001-01-25 CN CNB018041027A patent/CN1195743C/zh not_active Expired - Lifetime
- 2001-01-25 IL IL15053001A patent/IL150530A0/xx unknown
- 2001-01-25 DE DE60121294T patent/DE60121294T3/de not_active Expired - Lifetime
- 2001-01-25 EE EEP200200414A patent/EE05003B1/xx unknown
- 2001-01-25 HR HR20020625A patent/HRP20020625A2/hr not_active Application Discontinuation
- 2001-01-25 EA EA200200790A patent/EA005378B1/ru not_active IP Right Cessation
- 2001-01-25 BR BR0107815A patent/BRPI0107815B8/pt not_active IP Right Cessation
- 2001-01-25 EP EP01907700A patent/EP1250328B2/de not_active Expired - Lifetime
- 2001-01-25 CA CA2397636A patent/CA2397636C/fr not_active Expired - Lifetime
- 2001-01-25 DK DK01907700.7T patent/DK1250328T4/da active
- 2001-01-25 ES ES01907700T patent/ES2267715T5/es not_active Expired - Lifetime
- 2001-01-25 US US10/181,223 patent/US7034021B2/en not_active Expired - Lifetime
- 2001-01-25 YU YU55602A patent/YU55602A/sh unknown
- 2001-01-25 JP JP2001555064A patent/JP4926357B2/ja not_active Expired - Lifetime
- 2001-01-26 AR ARP010100337A patent/AR027293A1/es active IP Right Grant
2002
- 2002-07-03 ZA ZA2002/05314A patent/ZA200205314B/en unknown
- 2002-07-11 IS IS6467A patent/IS6467A/is unknown
- 2002-07-17 BG BG106933A patent/BG106933A/xx unknown
- 2002-07-22 MA MA26737A patent/MA25650A1/fr unknown
- 2002-07-24 NO NO20023532A patent/NO20023532L/no not_active Application Discontinuation
2005
- 2005-03-22 US US11/085,145 patent/US7452883B2/en not_active Expired - Lifetime
2006
- 2006-09-08 CY CY20061101287T patent/CY1105344T1/el unknown
2007
- 2007-10-30 US US11/976,936 patent/US7767676B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/979,140 patent/US20080108591A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1250328B1 (de)	2006-07-05
AU782307B2 (en)	2005-07-21
EE05003B1 (et)	2008-04-15
CA2397636C (fr)	2010-04-06
JP4926357B2 (ja)	2012-05-09
HUP0204087A2 (hu)	2003-04-28
HRP20020625A2 (en)	2003-10-31
PL357191A1 (en)	2004-07-26
NO20023532D0 (no)	2002-07-24
FR2804113B1 (fr)	2004-06-18
HU230790B1 (en)	2018-05-02
EP1250328A1 (de)	2002-10-23
CZ303445B6 (cs)	2012-09-19
WO2001055122A1 (fr)	2001-08-02
SI1250328T1 (sl)	2006-10-31
NO20023532L (no)	2002-09-25
CZ20022462A3 (cs)	2003-04-16
BR0107815A (pt)	2002-10-29
HK1050529A1 (en)	2003-06-27
CN1404472A (zh)	2003-03-19
US20080108591A1 (en)	2008-05-08
SI1250328T2 (sl)	2010-09-30
SK9762002A3 (en)	2003-05-02
US20050165022A1 (en)	2005-07-28
IS6467A (is)	2002-07-11
US7034021B2 (en)	2006-04-25
DE60121294T2 (de)	2007-08-30
YU55602A (sh)	2005-03-15
KR100722438B1 (ko)	2007-05-29
AU3560301A (en)	2001-08-07
ZA200205314B (en)	2005-07-27
MA25650A1 (fr)	2002-12-31
DE60121294D1 (de)	2006-08-17
IL150530A0 (en)	2003-02-12
US7767676B2 (en)	2010-08-03
AP2002002578A0 (en)	2002-09-30
EP1250328B2 (de)	2010-04-21
AR027293A1 (es)	2003-03-19
MXPA02007232A (es)	2003-10-15
US20080108619A1 (en)	2008-05-08
PT1250328E (pt)	2006-10-31
TNSN01012A1 (fr)	2005-11-10
EE200200414A (et)	2003-10-15
US7452883B2 (en)	2008-11-18
CA2397636A1 (fr)	2001-08-02
FR2804113A1 (fr)	2001-07-27
CN1195743C (zh)	2005-04-06
CY1105344T1 (el)	2010-03-03
SK287647B6 (sk)	2011-05-06
DK1250328T4 (da)	2010-06-28
EA005378B1 (ru)	2005-02-24
KR20020075395A (ko)	2002-10-04
EA200200790A1 (ru)	2003-02-27
US20030109530A1 (en)	2003-06-12
DE60121294T3 (de)	2010-09-23
ES2267715T5 (es)	2010-06-10
BRPI0107815B8 (pt)	2021-05-25
BG106933A (en)	2003-07-31
JP2003520858A (ja)	2003-07-08
ATE332294T1 (de)	2006-07-15
BRPI0107815B1 (pt)	2017-08-29
HUP0204087A3 (en)	2006-01-30
ES2267715T3 (es)	2007-03-16
PL205345B1 (pl)	2010-04-30
DK1250328T3 (da)	2006-10-30

Publication	Publication Date	Title
CA2397636C (fr)	2010-04-06	Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique
CH620925A5 (de)	1980-12-31
EP1257552B1 (de)	2004-08-18	Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis
US20100069451A1 (en)	2010-03-18	Salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7, 7a- octahydrobenzo[d]isoxazol-4-one
EP2313384B1 (de)	2013-09-18	Phenylalkylpiperazine mit tnf-modulierender wirkung
AU760147B2 (en)	2003-05-08	((Aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy
EP0005091B1 (de)	1981-11-25	Monosubstituierte Piperazine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
EP0103895A2 (de)	1984-03-28	Hydroxylamin-derivate, Herstellungsverfahren und Verwendung
JP2018517720A (ja)	2018-07-05	新規ホスホジエステラーゼ５阻害剤とその使用
US5049574A (en)	1991-09-17	5-trifluormethoxy-2-benzimidazolamine compounds
MC1576A1 (fr)	1985-02-04	Derives d'imidazole
EP0607077A1 (de)	1994-07-20	Salze von 4-Pyrimidinon Derivaten, deren Herstellung und deren Verwendung als Heilmittel
HK1050529B (en)	2006-09-29	Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
FR2483920A1 (fr)	1981-12-11	Nouveaux derives de quinazoline, leur procede de preparation et leur application en therapeutique
BE892084A (fr)	1982-08-10	Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments